Fourat Ridouani1, Mohamed M Soliman2, Ryan W England3, Meier Hsu4, Chaya S Moskowitz4, Raphael Doustaly1, Constantinos T Sofocleous1, F Edward Boas1, Hooman Yarmohammadi1, Amy R Deipolyi5. 1. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 2. Division of Interventional Radiology, Department of Radiology, New York Presbyterian Hospital/Weill Cornell Medicine, 525 East 68th Street, New York, NY, 10065, USA. 3. Division of Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Hospital, 1800 Orleans Street, Baltimore, MD, 21287, USA. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 5. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. Electronic address: deipolya@mskcc.org.
Abstract
PURPOSE: To determine the relationship of tumoral and nontumoral radiation dose to response and toxicity after transarterial radioembolization (TARE) of breast cancer liver metastasis. METHODS: This retrospective study evaluated all patients with breast cancer liver metastases treated with TARE (2/2011-6/2019). Extent of disease was measured as unilobar or bilobar on baseline PET/CT prior to TARE. Response was assessed for targeted regions with modified PERCIST criteria on first follow-up PET/CT. Tumoral and nontumoral liver dosimetry was evaluated by performing volumetric segmentation on post-TARE Bremsstrahlung SPECT/CT. ≥Grade 3 hepatotoxicity was defined as ≥grade 3 bilirubin/AST/ALT elevation or ascites requiring intervention. Fisher's exact tests, Wilcoxon rank sum tests, and Kaplan-Meier survival analysis were performed. RESULTS: Among 64 women, 60 patients had pre- and post-TARE PET/CT, of whom 46/60 (77 %) achieved objective response (OR). Responders received higher tumoral dose with a median (interquartile range) of 167 (96-217) vs. 54 (45-62) Gy (p < 0.001). ≥Grade 3 hepatotoxicity occurred in 8/64 (12.5 %) and was associated with higher pre-treatment bilirubin levels of 0.9 (0.9-1.1) vs. 0.5 (0.4-0.7) mg/dL (p = 0.013). Median overall survival (OS) was 11 (95 % CI 10-19) months. Bilobar disease (Hazard Ratio [HR]: 2.77, 95 % CI 1.11-6.89, p = 0.028) and elevated pre-TARE AST (HR 1.02, 95 % CI 1.01-1.03, p < 0.001) were independently associated with shorter survival. ≥Grade 3 hepatotoxicity was associated with reduced survival (p < 0.001). OR was associated with longer OS of 17 months, compared with 10 months (p = 0.027). CONCLUSION: In TARE for breast cancer liver metastasis, higher tumoral radiation dose (>79.5 Gy) was associated with OR, which was associated with longer survival. Pre-existing liver dysfunction was associated with hepatotoxicity, which was associated with decreased survival.
PURPOSE: To determine the relationship of tumoral and nontumoral radiation dose to response and toxicity after transarterial radioembolization (TARE) of breast cancer liver metastasis. METHODS: This retrospective study evaluated all patients with breast cancer liver metastases treated with TARE (2/2011-6/2019). Extent of disease was measured as unilobar or bilobar on baseline PET/CT prior to TARE. Response was assessed for targeted regions with modified PERCIST criteria on first follow-up PET/CT. Tumoral and nontumoral liver dosimetry was evaluated by performing volumetric segmentation on post-TARE Bremsstrahlung SPECT/CT. ≥Grade 3 hepatotoxicity was defined as ≥grade 3 bilirubin/AST/ALT elevation or ascites requiring intervention. Fisher's exact tests, Wilcoxon rank sum tests, and Kaplan-Meier survival analysis were performed. RESULTS: Among 64 women, 60 patients had pre- and post-TARE PET/CT, of whom 46/60 (77 %) achieved objective response (OR). Responders received higher tumoral dose with a median (interquartile range) of 167 (96-217) vs. 54 (45-62) Gy (p < 0.001). ≥Grade 3 hepatotoxicity occurred in 8/64 (12.5 %) and was associated with higher pre-treatment bilirubin levels of 0.9 (0.9-1.1) vs. 0.5 (0.4-0.7) mg/dL (p = 0.013). Median overall survival (OS) was 11 (95 % CI 10-19) months. Bilobar disease (Hazard Ratio [HR]: 2.77, 95 % CI 1.11-6.89, p = 0.028) and elevated pre-TARE AST (HR 1.02, 95 % CI 1.01-1.03, p < 0.001) were independently associated with shorter survival. ≥Grade 3 hepatotoxicity was associated with reduced survival (p < 0.001). OR was associated with longer OS of 17 months, compared with 10 months (p = 0.027). CONCLUSION: In TARE for breast cancer liver metastasis, higher tumoral radiation dose (>79.5 Gy) was associated with OR, which was associated with longer survival. Pre-existing liver dysfunction was associated with hepatotoxicity, which was associated with decreased survival.
Authors: Etienne Garin; Laurence Lenoir; Yan Rolland; Julien Edeline; Habiba Mesbah; Sophie Laffont; Philippe Porée; Bruno Clément; Jean-Luc Raoul; E Boucher Journal: J Nucl Med Date: 2012-02 Impact factor: 10.057
Authors: C Chiesa; M Mira; M Maccauro; C Spreafico; R Romito; C Morosi; T Camerini; M Carrara; S Pellizzari; A Negri; G Aliberti; C Sposito; S Bhoori; A Facciorusso; E Civelli; R Lanocita; B Padovano; M Migliorisi; M C De Nile; E Seregni; A Marchianò; F Crippa; V Mazzaferro Journal: Eur J Nucl Med Mol Imaging Date: 2015-06-27 Impact factor: 9.236
Authors: Wan-Yee Lau; Andrew S Kennedy; Yun Hwan Kim; Hee Kit Lai; Rheun-Chuan Lee; Thomas W T Leung; Ching-Sheng Liu; Riad Salem; Bruno Sangro; Borys Shuter; Shih-Chang Wang Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-13 Impact factor: 7.038
Authors: J E Dancey; F A Shepherd; K Paul; K W Sniderman; S Houle; J Gabrys; A L Hendler; J E Goin Journal: J Nucl Med Date: 2000-10 Impact factor: 10.057
Authors: Michael Vouche; Ali Habib; Thomas J Ward; Edward Kim; Laura Kulik; Daniel Ganger; Mary Mulcahy; Talia Baker; Michael Abecassis; Kent T Sato; Juan-Carlos Caicedo; Jonathan Fryer; Ryan Hickey; Elias Hohlastos; Robert J Lewandowski; Riad Salem Journal: Hepatology Date: 2014-05-27 Impact factor: 17.425
Authors: Max Seidensticker; Ricarda Seidensticker; Robert Damm; Konrad Mohnike; Maciej Pech; Bruno Sangro; Peter Hass; Peter Wust; Siegfried Kropf; Günther Gademann; Jens Ricke Journal: PLoS One Date: 2014-11-13 Impact factor: 3.240
Authors: Richard Wu; Keerthi Gogineni; Jane Meisel; Stephen Szabo; Meenakshi Thirunavu; Sarah Friend; Zachary Bercu; Ila Sethi; Neela Natarajan; Jeffrey Switchenko; Jason Levy; Eddie Abdalla; Laura Weakland; Kevin Kalinsky; Nima Kokabi Journal: Cardiovasc Intervent Radiol Date: 2022-08-25 Impact factor: 2.797
Authors: Max Seidensticker; Matthias Philipp Fabritius; Jannik Beller; Ricarda Seidensticker; Andrei Todica; Harun Ilhan; Maciej Pech; Constanze Heinze; Maciej Powerski; Robert Damm; Alexander Weiss; Johannes Rueckel; Jazan Omari; Holger Amthauer; Jens Ricke Journal: Cancers (Basel) Date: 2021-04-21 Impact factor: 6.639